Outcomes Study: Implementing and Scaling a Pharmacist-led Workflow to Increase Use of Weight-Beneficial Therapy for Type 2 Diabetes in a Health-System Specialty Pharmacy

Members of our team had the opportunity to present a new poster abstract at NASP inSPIRE 2026, which was held from September 22-25, 2026.

Authors

Andrew Wash, PharmD, PhD; Lauren Bryant, PharmD, CDCES; Nicole Prokopick, PharmD, MBA; Alison Calabrese, RPH; Courtney Ray, PharmD; Alexis Gately, PharmD, CSP; Beth Carpenter, PharmD; Nicholas McDonald, PharmD; Amber Skrtic, PharmD, CSP; Ana I. Lopez Medina, PharmD, PhD; Casey Fitzpatrick, PharmD; Jessica Mourani, PharmD

Background

• Updates to type 2 diabetes (T2D) guidelines emphasize weight management as being as important as glycemic control, yet many health systems lack processes to identify patients who may benefit and initiate evidence-based medications.¹

• Health-system specialty pharmacy (HSSP) expertise in navigating medication access and clinical monitoring, combined with health system integration, positions them to support care teams in guideline adoption.

Objectives

To describe a pilot pharmacist-led program within an HSSP that standardized patient identification, assessment, and recommendation workflows for guideline-directed, weight-beneficial pharmacotherapy in T2D, and to evaluate program outcomes and opportunities for implementation across multiple HSSPs.